Form 4: Blueprint Medicines Insider Disposes Shares Following Sanofi Merger Completion

Blueprint Medicines Corp's President of R&D, Fouad Namouni, disposed of all beneficial ownership in the company's common stock and derivative securities following the completion of its merger with Sanofi.

Summary

• Fouad Namouni, President of R&D for Blueprint Medicines Corp (BPMC), reported the disposition of all his beneficial ownership in the company's common stock and derivative securities.
• The transactions occurred on July 17, 2025, coinciding with the effective time of the merger between Blueprint Medicines Corp and Rothko Merger Sub, Inc., a wholly-owned subsidiary of Sanofi.
• Under the merger agreement, Sanofi's subsidiary completed a tender offer to acquire all outstanding shares of BPMC common stock for $129.00 per share in cash (the 'Cash Offer Price'), plus one contractual contingent value right (CVR) per share.
• Performance-based stock units (PSUs) were deemed earned based on the greater of target and actual performance, then cancelled and converted into the Offer Consideration (Cash Offer Price + CVR).
• Outstanding restricted stock units (RSUs), whether vested or unvested, were cancelled and automatically converted into the Offer Consideration.
• Fifty percent of PSUs and RSUs issued in calendar year 2025 were converted into cash-based awards subject to continued vesting, based on the Cash Offer Price plus one CVR for each underlying share.
• All outstanding stock options, whether vested or unvested, became fully vested, cancelled, and converted into the Cash Offer Price (less the applicable exercise price) plus one CVR per share.
• Fifty percent of stock options issued in calendar year 2025 were converted into cash-based awards subject to continued vesting, based on the Cash Offer Price (less the applicable exercise price) plus one CVR for each underlying share.
• Following these transactions, Fouad Namouni's beneficial ownership of Blueprint Medicines common stock and derivative securities is 0.

Sentiment

Score: 8

Explanation: The filing confirms the successful completion of a significant merger, providing shareholders with a clear cash value for their shares and potential upside through contingent value rights, which is generally a positive outcome for investors.

Positives

• The completion of the merger provides Blueprint Medicines shareholders with a defined cash value of $129.00 per share.
• The inclusion of a contractual contingent value right (CVR) offers shareholders potential additional payments upon the achievement of certain future milestones.

Negatives

• Blueprint Medicines Corp ceases to be an independent publicly traded entity, becoming an indirect wholly-owned subsidiary of Sanofi.
• The value of the contingent value rights (CVRs) is uncertain and dependent on the achievement of specific future milestones, which may or may not occur.

Risks

• The value of the contingent value rights (CVRs) is subject to the achievement of certain milestones, and there is no guarantee these milestones will be met, potentially resulting in no additional payments from the CVRs.

Future Outlook

Blueprint Medicines Corp is now an indirect wholly-owned subsidiary of Sanofi. The future outlook for former BPMC shareholders holding CVRs depends on the achievement of specific milestones that will trigger contingent payments.

Industry Context

This transaction represents a common strategic move in the pharmaceutical and biotechnology sectors, where larger companies like Sanofi acquire smaller, innovative firms like Blueprint Medicines to expand their pipeline, technology, or market presence.

Comparison to Industry Standards

• The document details an insider's equity transactions following a merger and does not provide financial or operational results that can be directly compared to global industry benchmarks or specific comparable companies/projects.

Stakeholder Impact

• Shareholders received a cash payment of $129.00 per share and one CVR per share, finalizing their investment in Blueprint Medicines.
• Employees, including the reporting person, had their equity awards converted into cash or cash-based awards, aligning with the merger terms.

Next Steps

• Monitoring the achievement of milestones related to the contingent value rights (CVRs) for potential future payments.

Key Dates

Keywords

Blueprint Medicines, BPMC, Sanofi, Merger, Acquisition, Tender Offer, Form 4, Insider Transaction, Stock Options, RSU, PSU, CVR, Pharmaceutical, Biotechnology